Superintelligence for the work that matters

Qor turns relevant evidence and expert methodology into decisions that stay current as the world changes
Proven foundations

Qor is built on BenevolentAI.

For more than a decade, BenevolentAI has developed and applied AI to complex scientific evidence and consequential decisions in life sciences.

Qor brings together that accumulated capability in scientific knowledge, evidence infrastructure, reasoning methods, machine learning, evaluation and domain expertise.

0+ years
Applying AI to life sciences
0+ patents
Across technology, methods and biology

Peer-reviewed research

Across AI, biomedical knowledge and drug discovery
The challenge

You don’t notice the moment your thinking goes out of date until it’s too late.

Your positioning and plans all sit on beliefs about the science, the market and the financial environment. Qor keeps every conclusion you hold under continuous test, and tells you when one stops being true.
Position

Know the whole field.

How crowded is this indication getting? What are comparable assets trading for right now?
Consequence

Know the implications.

Is this rival readout good or bad for our asset? Does it change the case for the raise?
Provenance

Know what changes, always.

Does the analysis we delivered still hold? What has changed since we last looked?
How QOR stacks up

All options today force a trade-off.

Qor fills the gap that exists when building a picture from data subscriptions and generic LLMs.
CapabilityQorDatabase toolsGeneric LLMsManual labour
Specific to an asset or indication
Applies expert reasoning consistently
Continuously updates with new informationdata onlyonly when askedif resourced
Understands evidence in your specific contextonly when given
Conclusions you can act onunverified
Board-ready in hoursunverified
Scales without adding headcount

See what Qor surfaces for your asset and indication.

Book a demo
Why Qor

Answers that survive a board challenge.

Each alternative leaves a gap. Qor gives you an answer you can stand behind.

01

Evidence-backed answers

How
Every factual claim goes through a source-verification pass before it reaches you.
vs
Manual fact-checking and hallucination risk.

02

The same analytical discipline, every time

How
Qor runs the same workflow on every update, so you can see what changed and why.
vs
Inconsistent workflows and outputs.

03

Coverage without the headcount

How
When a market moves, Qor works it through clinical design, BD, investor narrative, IP and runway.
vs
What changed, but not what it means.

04

A position that stays current

How
Qor reads the market continuously, updating your positions as the market moves around them.
vs
Analysis with an expiry date.

What customers tell us

"Qor has been helping plan near-future business development strategies, specifically by correlating information with the recent activities of investors and collaboration partners."

Dr. Mario Kuttke
Dr. Mario Kuttke
Head of Cell Therapy
Invios

"Competitor phase changes and programme discontinuations reach me without my going to look, which is the part I always used to miss."

Chief Executive
Single-asset biotech spinout

"Most solutions hand you a long text report; this presents it in a way you can actually trust and act on."

Director of Discovery
Metabolic disease biotech

"If I have a target asset of interest I can go in and run it myself. I do not need to raise a ticket with anyone's team and wait."

CI lead
R&D technologies, top-5 global pharma

"Exhaustive is the right default for us. We would rather filter down from everything than discover later that the analyst stopped at the obvious twenty."

Partner
Life sciences strategy consultancy

"It let us cover every autoimmune indication rather than the fifty that seemed closest. Going into a client conversation with that breadth behind you changes the conversation."

Partner
Global commercial and pricing consultancy

"As a non-executive director across several portfolio companies, I need to know what changed and what it means on assets I did not personally diligence. The high-impact digest does that. "

Non-Executive Director
Cell therapy portfolio company

    Discover the power of continuous intelligence today.

    Book a demo